European Pharmaceutical Review
JANUARY 11, 2024
The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies.
Pharmaceutical Technology
NOVEMBER 17, 2022
This delay in diagnosis ultimately leads to disease progression and associated complications, such as chronic pelvic pain and infertility, which greatly affects the patients’ quality of life. However, NICE stated it will further explore new approaches to address these unmet needs during scoping of the update.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Legacy MEDSearch
DECEMBER 12, 2022
Highmark), one of America’s leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, will conduct a targeted Coverage with Evidence program with the goal of providing its members with affordable treatment for episodic and chronic migraine. .
Legacy MEDSearch
JUNE 15, 2023
The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Rep-Lite
DECEMBER 7, 2023
Education Requirements Many pharmaceutical companies prefer pharmaceutical sales candidates with a bachelor’s degree in a relevant field, such as biology, chemistry, pharmacology, or a healthcare-related discipline. You should be able to discuss the benefits, side effects, and uses of the medications with healthcare professionals.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Pharmaceutical Technology
FEBRUARY 17, 2023
Most drugs being developed now are more tailored to specific mechanisms of action compared to past drugs, says Dr. Gareth Veal, PhD, a professor of cancer pharmacology at Newcastle University. The demand came amid concerns that the drug causes a slew of side effects such as nausea, diarrhea, and liver issues.
Expert insights. Personalized for you.
80 
Let's personalize your content